Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors.

Chalcone MTDL Monoamine oxidase Natural compounds Neurodegenerative diseases Selective MAO-B inhibitors

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 04 06 2020
revised: 07 07 2020
accepted: 07 07 2020
pubmed: 14 9 2020
medline: 20 4 2021
entrez: 13 9 2020
Statut: ppublish

Résumé

In the last years the continuous efforts in the development of novel and effective inhibitors of human monoamine oxidases (hMAOs) promoted the discovery of new agents able to effectively and selectively bound one of the two isoforms (hMAO-A and hMAO-B). However, the parent chalcone scaffold still covers an important role in hMAOs inhibition. In the present work, we focused our attention on the researches performed in the last five years, involving chalcones or compounds that can be correlated to them. We classified the chalcones into different groups depending on their structural characteristics or common molecular properties. In this regard, we also considered chalcones based on heterocycles and compounds endowed with scaffolds containing a masked chalcone motif. When structural attributes could not be used, we took advantage of enzymatic activity to arrange compounds in a group. We followed this approach for the multitarget agents. Finally, we also analysed the naturally occurring chalcones. All the sections were discussed exhaustively and the structure-activity relationship (SAR) analyses were sustained by means of detailed images describing the effects related to the substituents or structural changes.

Identifiants

pubmed: 32920430
pii: S0223-5234(20)30622-X
doi: 10.1016/j.ejmech.2020.112650
pii:
doi:

Substances chimiques

Chalcones 0
Monoamine Oxidase Inhibitors 0
Monoamine Oxidase EC 1.4.3.4

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112650

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Paolo Guglielmi (P)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. Electronic address: paolo.guglielmi@uniroma1.it.

Bijo Mathew (B)

Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, 678557, Kerala, India. Electronic address: bijovilaventgu@gmail.com.

Daniela Secci (D)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. Electronic address: daniela.secci@uniroma1.it.

Simone Carradori (S)

Department of Pharmacy, "G. D'Annunzio" University of Chieti-Pescara, Via Dei Vestini 31, 66100, Chieti, Italy. Electronic address: simone.carradori@unich.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH